3-(1H-Indol-2-yl)phenyl)(3,4,5-trimethoxyphenyl)methanone (I-387) is a novel indole compound with antitubulin action and potent antitumor activity in various preclinical models. I-387 avoids drug resistance mediated by P-glycoprotein and showed less neurotoxicity than vinca alkaloids during in vivo studies. We examined the pharmacokinetics and metabolism of I-387 in mice as a component of our preclinical development of this compound and continued interest in structure-activity relationships for antitubulin agents. After a 1 mg/kg intravenous dose, noncompartmental pharmacokinetic analysis in plasma showed that clearance (CL), volume of distribution at steady state (Vd ss ), and terminal half-life (t 1/2 ) of I-387 were 27 ml per min/kg, 5.3 l/kg, and 7 h, respectively. In the in vitro metabolic stability study, half-lives of I-387 were between 10 and 54 min by mouse, rat, dog, monkey, and human liver microsomes in the presence of NADPH, demonstrating interspecies variability. I-387 was most stable in rat liver microsomes and degraded quickly in monkey liver microsomes. Liquid chromatography-tandem mass spectrometry was used to identify phase I metabolites. Hydroxylation, reduction of a ketone group, and O-demethylation were the major metabolites formed by the liver microsomes of the five species. The carbonyl group of I-387 was reduced and identified as the most labile site in human liver microsomes. The results of these drug metabolism and pharmacokinetic studies provide the foundation for future structural modification of this pharmacophore to improve stability of drugs with potent anticancer effects in cancer patients.
Introduction
3-(1H-Indol-2-yl)phenyl)(3,4,5-trimethoxyphenyl)methanone (I-387) , is a new antitubulin agent with potent in vivo and in vitro antitumor activity in various preclinical cancer models (Fig. 1A) (Ahn et al., 2010) . I-387 destabilizes microtubules by binding to the colchicine-binding domain. In addition, I-387 is not a substrate for ATP-binding cassette transporters and maintained potent tumor growth inhibition in xenograft models using cell lines overexpressing P-glycoprotein. This investigational agent is particularly attractive for further development because no significant neurotoxicity was observed during in vivo and in vitro neurotoxicity studies (Ahn et al., 2010) . To this end, we sought to understand the absorption, distribution, metabolism, and excretion of I-387 as a means to evaluate its toxicity and potency and to optimize the I-387 pharmacophore for better exposure and stability in vivo.
Because it is necessary to achieve and maintain effective concentrations of drugs at their sites of actions, pharmacokinetic studies to characterize absorption, distribution, metabolism, and elimination are important in optimization of therapeutic dose and schedule. Although in vivo studies provide definitive data regarding the disposition of a drug in an animal, in vitro studies of drug metabolism provide the opportunity for efficient and rapid characterization of the metabolic fate of a compound in numerous species without the need for synthesis of large quantities of drugs or use of animals. Drug biotransformation is divided into two types of reactions: phase I (hydrolysis, oxidation, and reduction) and phase II (conjugation). The cytochrome P450 enzyme superfamily plays a dominant role in phase I metabolism, and phase II conjugation is caused by UDP-glucuronosyltransferase, N-acetyl transferase, glutathione transferase, sulfotransferase, and so on (Schlichting et al., 2000; Sheweita, 2000) . Although the isolated perfused liver could give an excellent representation of the in vivo situation, current guidelines for human drug development allow the use of in vitro systems for metabolism studies, including microsomes, Supersomes, cytosol, the S9 fraction, cell lines, transgenic cell lines, and primary hepatocytes (FDA Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro, http:// www.fda.gov) (Brandon et al., 2003) .
In this study, we examined the pharmacokinetics of I-387 in mice after intravenous, intraperitoneal, and oral dosing in mice. The in vitro metabolic fate of I-387 was investigated in mouse, rat, dog, monkey, and human liver microsomes. Our studies provide the first evidence that intravenous and intraperitoneal administration of I-387 in mice can achieve systemic drug exposure sufficient for an in vivo antitumor effect (Ahn et al., 2010) . In addition, we identified a metabolically labile site in the I-387 pharmacophore that can be modified to design more stable drug candidates.
Materials and Methods
Chemicals, Microsomes, and Animals. I-387and a putative metabolite of I-387 were synthesized using methods similar to these described previously for indole-15 (Ahn et al., 2011) . In this study, indole-15 was used as an internal standard. Intermediate 1 was treated with 3,4,5-trimethoxyphenyllithium to afford alcohol 2 (Fig. 1A) . Alcohol 2 was then oxidized with pyridinium dichromate in dichloromethane at room temperature to form ketone 3, which was deprotected with aqueous sodium hydroxide to afford I-387 (Fig. 1A) . The putative metabolite, alcohol 4, was also synthesized by deprotection of compound 2 with reflux under basic conditions (Fig. 1A) . Complete details of synthesis are forthcoming in a separate publication.
Pooled liver microsomes from mice, rats, dogs, monkeys, and humans were purchased from XenoTech, LLC (Lenexa, KS). The NADPH-regenerating system was purchased from BD (Franklin Lakes, NJ). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Male ICR mice (20 -25 g) were purchased from Harlan Biosciences (Indianapolis, IN). All animal protocols were approved by the animal care and use committee at The Ohio State University or the University of Tennessee Health Science Center.
Pharmacokinetic Studies in Mice. Male ICR mice (5-6 weeks, 20 -25 g) were used. For I-387, three doses (1, 5, and 15 mg/kg) were administered via the intravenous, intraperitoneal, and oral routes. Dosing vehicles were composed of 10% dimethyl sulfoxide in PEG300. Intravenous doses were administered via the tail vein. Oral doses were administered by gavage. At each time point, three to four mice were euthanized by isoflurane (Baxter Healthcare, Deerfield, IL), and blood samples (up to 600 l each) were taken from the posterior vena cava. Plasma samples were stored at Ϫ20°C before analysis.
Sample Preparation for LC-MS/MS Analysis of Mouse Pharmacokinetics. Plasma proteins were precipitated by the addition of acetonitrile (150 l, containing the internal standard) to 100 l of mouse plasma. Samples were vortexed and then centrifuged at 8000g for 10 min. The supernatant was transferred to a clean vial for injection into the mass spectrometer for analysis.
Pharmacokinetic Data Analysis. Mean plasma concentration-time data were analyzed using noncompartmental methods (WinNonlin version 5.2.1; Pharsight Corporation, Mountain View, CA). The area under the plasma concentration-time curve from time 0 to infinity (AUC inf ) was calculated by the trapezoidal rule with extrapolation to time infinity. The terminal t 1/2 was calculated as ln2/ z , where z was the first-order rate constant associated with the terminal (log-linear) portion of the curve. The plasma CL was calculated as dose/AUC inf . The maximum plasma concentration (C max ) and the time when it occurred (T max ) were obtained by visual inspection of the plasma concentration-time curve. The apparent Vd ss was calculated by CL ϫ MRT inf , where MRT is the mean residence time extrapolated to infinity calculated as AUMC inf / AUC inf , where AUMC inf is the area under the first moment curve extrapolated to infinity. The bioavailability (F) was calculated as (AUC non-i.v 
In Vitro Metabolism Studies. For both phase I and phase I and II metabolism studies, animal microsomes was used as described previously . In brief, the incubation mixture consisted of 1 mg/ml liver microsomal proteins, 3 mM NADPH, and 0.5 M test compound in 65 mM potassium phosphate buffer (pH 7.4). The concentration of 0.5 M was selected for these studies on the basis of preliminary experiments showing that the K m value for metabolism was Ͼ10 M. For the phase I and II metabolism, 5 mM UDPglucuronic acid (UDPGA), 5 mM D-saccharolactone, 50 g/ml alamethicin, and 3 mM magnesium chloride were added to the phase I metabolism study mixture. The concentration of methanol (used for dissolving the substrate) was 1% (v/v). The total volume of the incubation was 200 l, and the reaction mixtures were incubated at 37°C. For metabolite identification, the reaction mixture was incubated for 2 h. To generate stability curves for I-387 different incubations were stopped at 10, 20, 30, 60, and 90 min for analysis of I-387 remaining. All reactions were stopped by the addition of 200 l of ice-cold acetonitrile containing an internal standard for quantification. The samples were then centrifuged at 8000g for 5 min, and supernatant was analyzed by LC-MS/MS. The mean peak area ratio of I-387 to internal standard observed at time 0 was 100%. Replicate studies were conducted on at least two separate occasions for each species.
LC-MS/MS Analyses. The LC-MS/MS analysis was performed on a 4000 Q TRAP triple quadrupole/linear ion trap mass spectrometer (Applied Biosciences, Foster City, CA) with a nanospray interface. The nanospray temperature was set as 500°C, curtain gas at 30 psi, ion spray energy at 5500 V, nebulizer gas (gas 1) at 30, and nano gas (gas 2) at 40 psi. Nitrogen was used as the collision gas. The collision energy was 45 eV. The protonated molecules were investigated. Aliquots of samples were injected into the high-performance liquid chromatography system (model 1100 series ChemStation; Agilent Technologies, Santa Clara, CA). The gradient mode was used to achieve separation of the analytes using mixtures of mobile phase A (95% water and 5% acetonitrile with 0.1% formic acid) and mobile phase B (95% acetonitrile and 5% water with 0.1% formic acid) at a flow rate of 300 l/min.
Samples for pharmacokinetic studies were separated with a Halo 2.1 ϫ 50 mm C18 column (Advanced Materials Technology, Wilmington, DE) within a FIG. 1. Synthesis scheme. A, synthesis of I-387. Reagents and conditions: a, 3,4,5-trimethoxyphenyllithium, tetrahydrofuran, Ϫ78°C; b, pyridinium dichromate, CH 2 Cl 2 ; c, aqueous NaOH, EtOH, reflux. For better understanding putative structures of I-387 metabolites, we will refer to sections denoted in the figure as the A, B, and C rings. B, the structure of indole-15 (internal standard).
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at ASPET Journals on April 4, 2017 dmd.aspetjournals.org runtime of 8 min. Mobile phase A was used at 80% from 0 to 1 min followed by a linearly programmed gradient to 80% of mobile phase B within 1.5 min, and 80% of mobile phase B was maintained for 2 min before a quick ramp to 20% mobile phase B for 30 s. Then 20% of mobile phase B and 80% of mobile phase A were continued for another 3 min toward the end of analysis. Multiple reaction monitoring mode scanning of m/z 388.2 3 192 was used to obtain the most sensitive signals for I-387.
Metabolite separation was performed on an Alltima HP 2.1 ϫ 100 mm C18 column (Alltech Associates, Deerfield, IL). Total run time was 15 min. The mobile phase comprised 100% A for the first 1 min and increased to 100% B in a linear gradient over 7 min. Then 100% of mobile phase B was maintained for 2 min, and it quickly returned to 0% for 30 s; 100% mobile phase A was continued for 4.5 more min until the end of analysis. Q1 full (data were not shown), precursor ion, neutral loss, and enhanced product ion scan modes were used to identify metabolites of I-387.
Results
Pharmacokinetics of I-387 in Mice. Doses of 1, 5, and 15 mg/kg were administered via the intravenous, intraperitoneal, and oral route to elucidate the pharmacokinetic parameters of I-387 in ICR mice. Plasma concentrations of I-387 in mice declined in a biexponential manner after intravenous injection, with a terminal t 1/2 of 4 to 9 h. The Vd ss of I-387 was 3.8 to 9.8 l/kg after intravenous administration indicating high tissue binding. The high tissue binding of I-387 is probably a result of the hydrophobic nature of this compound. The estimated logP and clogP values of I-387 were 4.15 and 4.77, respectively (ChemDraw Ultra version 11.0; CambridgeSoft Corporation, Cambridge, MA). CL slightly decreased with increasing dose for the 1, 5, and 15 mg/kg with values of 27, 21, and 19 ml per min/kg, respectively (Table 1; Supplemental Fig.  1 ), which is 40 to 60% of hepatic plasma flow (Davies and Morris, 1993) . MRT inf increased from 3 and 3.3 h at the 1 and 5 mg/kg doses, respectively, to 8.8 h after the 15 mg/kg dose after intravenous administration (Table 1) . After intraperitoneal administration, I-387 was absorbed quickly with T max values of 5 to 10 min. Systemic exposure after intraperitoneal doses was 65 to 95% of the analogous intravenous dose (Table 1; Supplemental Fig. 2 ). Plasma concentrations of I-387 peaked at approximately 30 min after oral administration with absolute bioavailability of 24, 13, and 8% after doses of 1, 5, and 15 mg/kg, respectively (Table 1; Supplemental   Fig. 3) . A drug administered by intraperitoneal injection is subject to the same potential hepatic first-pass metabolism as oral administration. However, the intraperitoneal bioavailability (65-95%) of I-387 greatly exceeded that of orally administered drug (8 -24%), suggesting that the oral bioavailability of I-387 was primarily limited by its poor stability in gastric or intestinal fluids and/or gut wall metabolism or its incomplete absorption because of poor permeability and/or low aqueous solubility. The approximate terminal t 1/2 (mean t 1/2 ϭ 7 h) after intravenous administration was similar to that observed after intraperitoneal and oral doses (mean t 1/2 ϭ 7-8 h) (Table 1) .
Metabolic Stability of 387 in Mouse, Rat, Dog, Monkey, and Human Liver Microsomes. Metabolic stability was investigated by incubating I-387 with liver microsomes from mouse, rat, dog, monkey, and human. To evaluate the metabolism by phase II conjugation, UDPGA was introduced to the microsomal preparation. Half-life was determined with a two-parameter single exponential decay curves using SigmaPlot (version 10.0; Systat Software, Inc., Chicago, IL). Metabolic stability of I-387 in the presence and absence of UDPGA was not significantly different as evidenced by similar half-lives during incubation with phase I and phase I and II systems (Table 2 ). This result suggests that the primary metabolic pathway of I-387 predominantly involves phase I enzymes. I-387 was most stable in rat liver microsomes with the longest t 1/2 (41.9 min) and degraded quickly in monkey liver microsomes with the shortest t 1/2 (15 min) in phase I metabolism. The phase I metabolic stability of I-387 in human liver microsomes (23.6 min) appears to be more similar to those of mouse and dog with half-lives of 36.7 and 29.4 min, respectively, than those of the other two species.
Identification of Metabolites in Human Liver Microsomal Incubation. To identify metabolites in human liver microsomes, I-387 was incubated with human liver microsomes in the presence of NADPH for 2 h. Samples were analyzed by LC-MS/MS. Total ion current chromatograms of the acetonitrile extracted I-387 in precursor ion and neutral loss scan modes are shown in Fig. 2 . The results are described using the terms of A, B, and C rings of I-387 as shown in Fig. 1 . The product ion spectrum of I-387 (m/z 388.2) results in two prominent fragment ions of m/z 192 and 220 (Fig. 3A) . Thus, the precursor ion scan of m/z 192 and the neutral loss scan of m/z 167 were used to identify metabolites of I-387 and its product fragments. The precursor ion scan of m/z 192 was used to identify modifications in the carbonyl group and/or C ring, whereas metabolites containing metabolic modifications in rings A or B or the carbonyl could be identified by the neutral loss of 167 m/z.
In addition to unchanged I-387, three metabolites (M1, M2, and M3) were detected after a 2-h incubation in human liver microsomes (Fig. 2) . In the precursor scan mode, M1 showed the [M ϩ H] ϩ ion at m/z 374.7, which was 13.5 amu lower than that of the parent ion at m/z 390.6, which was 2.4 amu higher than that of the parent compound. These results suggest that the carbonyl group was reduced. M3 showed the [M ϩ H] ϩ ion at m/z 404.7, which was 16.5 amu higher than that of the parent compound in the neutral loss scan mode, indicating the addition of an oxygen atom to the A or B ring of parent compound. The fragment ion masses of M1, M2, and M3 obtained in the product ion spectrum clearly indicated O-demethylation in the C ring, reduction of the carbonyl group between rings B and C, and hydroxylation in the A or B ring (Fig. 3) . The structure of M2 was verified using a synthetic reference standard.
Metabolites of I-387 in Mouse, Rat, Dog, Monkey, and Human Liver Microsomes. To compare its metabolic fate in different species, I-387 was incubated for 2 h with mouse, rat, dog, and monkey liver microsomes under the same conditions applied to the human liver microsomes. The total ion current chromatogram of the linear ion trap product ion scan for m/z 375, 390.5, and 404.5 for each species is shown in Fig. 4 . Nine metabolites (M1-M9) were observed in mouse, rat, dog, and monkey liver microsomes. Table 3 shows the retention time, [M ϩ H] ϩ , and major fragment ions of I-387 and its metabolites in the liver microsomal incubations of the five species. In the EIC of m/z 375 and 404.5, additional metabolites (M4, M8, and M9) were observed, with different retention times than M1 and M3. M4 yielded the same fragment ion at m/z 192 as M1. Both M8 and M9 generated the characteristic fragment ion at m/z 208 as did M3. In the EIC of m/z 390.5, not only was the metabolite with the reduced carbonyl group (M3) detected but additional metabolites (M5, M6, and M7) were also found. The LC-MS/MS fragmentation pattern of M5, M6, and M7 yielded the characteristic fragment ion at m/z 208, indicating that demethylation and hydroxylation occurred.
The amount of each metabolite was obtained from peak areas in the EIC (Fig. 4) . The metabolism of I-387 in monkey and human liver microsomes showed similar patterns, with reduction of the carbonyl group and hydroxylation. In dog liver microsomes, hydroxylation was the primary metabolic pathway. Dog liver microsomes generate three different hydroxylated metabolites (M3, M8, and M9). M3 and/or M8 were also observed in the microsomes of other species. O-Demethylation was observed to a lesser degree in dog, monkey, and human microsomes. Incubation of mouse and rat liver microsomes with I-387 produced the reduced carbonyl, Odemethylated, and hydroxylated metabolites in similar proportions. Monkey liver microsomes produced patterns of metabolism of I-387 similar to those of human liver microsomes in vitro. Figure  5 depicts the proposed metabolic pathways of I-387 in the liver microsomes of the five species.
Discussion
Microtubules have been considered to be one of the major and best targets for cancer chemotherapy for decades. Despite the clinical successes of several antitubulin agents including vinca alkaloids and taxane analogs, toxicity and drug resistance have limited the effectiveness of antimitotic agents in clinical use (Dumontet and Sikic, 1999; Verrills and Kavallaris, 2005; Malik and Stillman, 2008) . We identified a novel compound, I-387, that inhibits the in vitro growth of a number of human cancer cell lines with nanomolar IC 50 values. I-387 inhibits tubulin polymerization via the colchicine binding site and circumvents P-glycoprotein- 
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at ASPET Journals on April 4, 2017 dmd.aspetjournals.org mediated multidrug resistance. An in vivo tumor xenograft study using immunodeficient mice provided compelling evidence of the ability of I-387 to inhibit tumor growth. Furthermore, in vitro and in vivo studies showed that I-387 was less neurotoxic than vinblastine and vincristine, tubulin destabilizers with known neurotoxicity at equieffective doses.
For the pharmacokinetic studies of I-387 in ICR mice, three doses (1, 5, and 15 mg/kg) of I-387 were administered via the intravenous, intraperitoneal, and oral route. Noncompartmental pharmacokinetic analysis after intravenous injection of I-387 showed that it has a large volume of distribution and low clearance in mice. The relatively long half-life of I-387 after intravenous, intraperitoneal, and oral administration provides the opportunity for less frequent dosing. The bioavailability of I-387 was Ͼ65 and Ͻ24% after intraperitoneal and oral administration, respectively. Therefore, intraperitoneal injection achieved sufficient exposure to I-387 compared with intravenous injection, without the technical complications or potential morbidity associated with repetitive intravenous or oral administration. In the recent xenograft study, 10 mg/kg I-387 was administered via intraperitoneal injection and induced 68 and 76% tumor growth inhibition (Ahn et al., 2010) . The pharmacokinetic study showed that plasma concentrations of I-387 (15 mg/kg i.p.) were maintained at Ͼ71 ng/ml for 30 h, suggesting that systemic drug concentrations approaching 50 ng/ml are necessary to achieve an in vivo antitumor effect. The low to moderate oral bioavailability of I-387 suggests that additional structural modifications may present a plausible approach to identifying an antitubulin agent that could be administered orally. We reported recently the synthesis and promising in vitro and in vivo anticancer activity of a series of 2-aryl-4-benzoyl-imidazoles with greatly improved aqueous solubility (Chen et al., 2010) as an advance toward this goal.
In vitro metabolic stability in liver microsomes of five different species was examined in the presence of NADPH. I-387 was metabolized mainly via phase I pathways in mouse, rat, dog, monkey, and human liver microsomes. Because I-387 showed stability in mouse and dog liver microsomes similar to that in human liver microsomes, further efficacy studies in mice and pharmacokinetic studies in dogs might be helpful to predict the effects of I-387 in humans compared with those in the other two species. In vitro metabolite identification studies showed that carbonyl reduction, O-demethylation, and/or hydroxylation are probably the predominant metabolic pathways for I-387. The positions of hydroxylation and/or demethylation varied between species. Quantitative differences in metabolism were also observed in the liver microsomes of different species. As a result, carbonyl reduction was the most important metabolic pathway in humans, suggesting that further modification in the carbonyl linkage could improve metabolic stability of this structural pharmacophore in humans.
In conclusion, a promising antitubulin agent, I-387, was slowly cleared, moderately distributed, and moderately metabolized in mice. The metabolic fate of I-387 varied among species. The metabolic identification study indicates that further structural optimization of I-387 in the carbonyl linkage could improve metabolite stability, and the inclusion of heterocyclic rings instead of the phenyl B-ring linkage may improve aqueous solubility and oral bioavailability. Our study suggests that further structural optimization of I-387 will lead to the development of new orally available antitubulin agents for the treatment of drug-resistant cancer. 
